IPO TERMS REVISED
FullPAC, Inc.GOTV · Nasdaq
$5–$5 / share$19.6M raise3,915,995 shares

FullPAC sets Nasdaq IPO at $5 a share for 3.92 million shares

FullPAC locked its terms at a flat $5 a share for roughly 3.92 million shares, a microcap Nasdaq debut worth about $19.6 million at the midpoint. A fixed price with no range means the deal is set, and the only question left is when it prices.

Source: SEC filing
IPO TERMS REVISED
Veri MedTech Holdings, Inc.VRHI · Nasdaq
$4–$4 / share$15M raise3,750,000 shares

Veri MedTech fixes IPO at $4 for a $15 million Nasdaq raise

Seven amendments in, Veri MedTech has locked its terms at a flat $4 a share for 3.75 million shares, a $15 million Nasdaq raise with Network 1 Financial Securities as sole underwriter. A fixed price and a single small underwriter mean this deal either clears at $4 or does not clear at all.

Source: SEC filing

Sponsored

Twelve Tabs, One Thesis

Your Research Resets Every Morning

The quote page in one tab. Filings in another. A chart you rebuilt from scratch, a transcript you never went back and found, a screener whose settings you will redo next week. Nothing you built yesterday is still there.

AlphaSpace replaces all of it with one screen you arrange yourself. Earnings calendar, estimate versus actual, the call transcript, live news, your own charts, every panel wired to whatever ticker you click. Close the browser and it is all still sitting there tomorrow.

See What a Built View Looks Like →

(Sponsor)

THE IPO WIRE
Retension Pharmaceuticals, Inc.RTSN · Nasdaq

Retension Pharmaceuticals files for Nasdaq IPO

Another biotech is testing the reopened IPO window: Retension Pharmaceuticals registered an S-1 to list on Nasdaq. Leerink Partners, Guggenheim Securities, Oppenheimer and Titan Partners are running the books, a four-bank syndicate that signals a real deal. Terms and deal size come with the first amendment.

Source: SEC filing
THE IPO WIRE
TRex Bio, Inc.TRXB · Nasdaq

TRex Bio files for Nasdaq IPO with five banks behind it

TRex Bio filed its S-1 to list on Nasdaq with a five-bank syndicate behind it. Terms are not set yet, so the price range in the next amendment is the number that decides whether this Treg-focused biotech gets priced into the record 2026 listing run.

Source: SEC filing
IPO PRICED
Electra Therapeutics, Inc.ETRA · Nasdaq
$15 / share$350M raise23,333,334 shares

Electra Therapeutics prices $350 million IPO at $15 a share

Electra Therapeutics priced at $15 a share, pulling in roughly $350 million, one of the larger biotech raises of the year. Jefferies, TD Cowen, Evercore ISI and Cantor led the deal, and trading opens with the full 23.3 million shares in public hands.

Source: SEC filing

Bloomberg's ETF analyst says the bipartisan overlap between the Democrat and Republican congressional trading ETFs is the group beating the market.

Looking at $NANC and $GOP which offer baskets of the personal stock holdings of politicians in each party we found that a portfolio of the stocks that BOTH sides own (overlapping names) does the best and has easily beaten that market via @psarofagis https://t.co/v8ZfjFMR8a
  • Replies5
  • Reposts0
  • Likes6
Biggest movers · At the close
  • MARAMarathon Digital$13.21+13.5%
  • SNDKSanDisk$1,787.02+10.7%
  • CIFRCipher Mining$18.27+7.9%
  • COHRCoherent$318.27+7.5%
  • IRENIren$46.53+7.0%
  • SMRNuScale Power$8.32-7.9%
  • IQiQIYI$1.01-7.7%
  • ASANAsana$9.45-6.4%
  • QCOMQualcomm$178.02-5.7%
  • GMGeneral Motors$82.35-4.9%

Bitcoin miners owned Thursday's close, led by Marathon Digital finishing 13.5% higher, with Cipher Mining and Iren both up 7% or more. Large-cap losses ran heavier than usual, with Qualcomm off 5.66% and General Motors down 4.93%.